Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Expert Insights

Andrew Evens, DO, MBA, MSc
Videos
Predicting Long-Term Effects Among Patients Treated for Early-Stage Hodgkin Lymphoma
09/07/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates &...
09/07/2023
Oncology
Monique Hartley Brown, MD, MMSc
Videos
Initiating Improvements in Access and Diversity in Clinical Trials for Patients With Multiple Myeloma
09/07/2023

Featuring Monique Hartley-Brown, MD, MMSc

Featuring Monique Hartley-Brown, MD, ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Monique Hartley-Brown, MD, MMSc, discusses initiatives to improve diversity and accessibility in clinical trials for patients with MM.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Monique Hartley-Brown, MD, MMSc, discusses initiatives to improve diversity and accessibility in clinical trials for patients with MM.
At the 2023 Great Debates &...
09/07/2023
Oncology
Andrew Yee, MD
Videos
Selecting Optimal Treatments for Patients With Relapsed Multiple Myeloma
09/06/2023

Featuring Andrew Yee, MD

Featuring Andrew Yee, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates &...
09/06/2023
Oncology
Kami J. Maddocks, MD
Videos
Pirtobrutinib Demonstrates Durable Efficacy and Safety Among Patients With Covalent BTK Inhibitor Pretreated R/R MCL
09/05/2023

Featuring Kami J. Maddocks, MD

Featuring Kami J. Maddocks, MD ...
Kami J. Maddocks, MD, analyzes the updated results of the BRUIN trial on the efficacy and safety of pirtobrutinib among patients with high-risk heavily pretreated R/R mantle cell lymphoma with prior covalent BTK inhibitor therapy.
Kami J. Maddocks, MD, analyzes the updated results of the BRUIN trial on the efficacy and safety of pirtobrutinib among patients with high-risk heavily pretreated R/R mantle cell lymphoma with prior covalent BTK inhibitor therapy.
Kami J. Maddocks, MD, analyzes...
09/05/2023
Oncology
Ernst Holler, MD
Videos
Exploring Mechanisms and Approaches for Graft-Versus-Host Disease Prophylaxis
09/05/2023

Featuring Ernst Holler, MD

Featuring Ernst Holler, MD
Ernst Holler, MD, provides insights and analyses regarding the latest mechanisms and approaches for graft-versus-host disease prophylaxis, explaining the latest evolution of T-cell interaction methods.
Ernst Holler, MD, provides insights and analyses regarding the latest mechanisms and approaches for graft-versus-host disease prophylaxis, explaining the latest evolution of T-cell interaction methods.
Ernst Holler, MD, provides...
09/05/2023
Oncology
Ernst Holler, MD
Videos
Analyzing Risk Factors for Acute and Chronic Graft-Versus-Host Disease
09/05/2023

Featuring Ernst Holler, MD

Featuring Ernst Holler, MD
Ernst Holler, MD, provides expert insights into the latest data on risk factors for the development of acute and chronic graft-versus-host disease.
Ernst Holler, MD, provides expert insights into the latest data on risk factors for the development of acute and chronic graft-versus-host disease.
Ernst Holler, MD, provides...
09/05/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Antibody Drug Conjugates for the Frontline Treatment of Patients With Advanced-Stage Hodgkin Lymphoma
09/05/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
Andrew Evens, DO, MBA, MSc, analyzes the first-line treatment landscape for patients with advanced-stage Hodgkin lymphoma through the integration of antibody drug conjugates, at the 2023 Great Debates & Updates in Hematologic Malignancies...
Andrew Evens, DO, MBA, MSc, analyzes the first-line treatment landscape for patients with advanced-stage Hodgkin lymphoma through the integration of antibody drug conjugates, at the 2023 Great Debates & Updates in Hematologic Malignancies...
Andrew Evens, DO, MBA, MSc,...
09/05/2023
Oncology
Daniel DeAngelo, MD, PhD
Videos
Promising Outcomes of FGFR1 Inhibitor Pemigatinib for Myeloid Lymphoid Neoplasms
08/28/2023

Featuring Daniel DeAngelo, MD, PhD

Featuring Daniel DeAngelo, MD, PhD ...
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD,...
08/28/2023
Oncology
Shinichi Nishina, MD, Kurashiki Central Hospital
Videos
RAS Status in ctDNA After Chemotherapy Among Patients With RAS-Mutant Colorectal Cancer
08/28/2023

Featuring Shinichi Nishina, MD

Featuring Shinichi Nishina, MD ...
At the 2023 World Congress on Gastrointestinal Cancers, Shinichi Nishina, MD, reported data on that RAS status in ctDNA of patients with RAS-mutant metastatic colorectal cancer who responded to first- or second-line chemotherapy.
At the 2023 World Congress on Gastrointestinal Cancers, Shinichi Nishina, MD, reported data on that RAS status in ctDNA of patients with RAS-mutant metastatic colorectal cancer who responded to first- or second-line chemotherapy.
At the 2023 World Congress on...
08/28/2023
Oncology
Irit Ben-Aharon, MD, PhD, Fishman Oncology Center
Videos
Increasing Incidence of Early-Onset Colorectal Cancer
08/28/2023

Featuring Irit Ben-Aharon, MD, PhD

Featuring Irit Ben-Aharon, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Irit Ben-Aharon, MD, PhD discussed how the incidence of early-onset colorectal cancer has risen over the past 2 decades.
At the 2023 World Congress on Gastrointestinal Cancers, Irit Ben-Aharon, MD, PhD discussed how the incidence of early-onset colorectal cancer has risen over the past 2 decades.
At the 2023 World Congress on...
08/28/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement